![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgQzMXgO8lQ-w0XEWlX5CJLskA1wKDxAoWt0XV3GHXBRA9E7ivb4kjSCoaX1Bhxl4AKi_iAtQRGbZ7EFOKC12_gcSSNZW9LjJ4161DN8UxDCbdz_zhzYLnvpVTOlvGKRBjg1nCD07aNZWHZ/s200/jmn30055f1.jpg)
When you're talking about some of the newer biologic agents, you may find that they're easy to mix up. Here's a helpful guide regarding nomenclature.
Abbreviations placed at the ends of the names convey specific information relating to their structure:
* "-cept" refers to fusion of a receptor to the Fc part of human IgG1
* "-mab" indicates a monoclonal antibody (mAb)
* "-ximab" indicates a chimeric mAb
* "-zumab" indicates a humanized mAb
Etanercept is a classic example of a TNF receptor fusion protein. Infliximab is a chimeric mAb directed against TNF. Certolizumab and tocilizumab are humanized mAbs.
No comments:
Post a Comment